RIPRETINIB IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMOURS (INVICTUS): A DOUBLE-BLIND, RANDOMISED, PLACEBO-CONTROLLED, PHASE 3 TRIAL

EVENT-FREE SURVIVAL BY RESIDUAL CANCER BURDEN WITH PEMBROLIZUMAB IN EARLY-STAGE TRIPLE NEGATIVE BREAST CANCER (TNBC): EXPLORATORY ANALYSIS FROM KEYNOTE-522